Winton Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Winton Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,485	Closed	-$615K	–	1539
2021 Q3	$615K	Sell	30,485 -3,661	-11%	-$101K	0.03%	755
2021 Q2	$1.27M	Sell	34,146 -173	-0.5%	-$5.3K	0.07%	395
2021 Q1	$878K	Buy	34,319 +1,643	+5%	+$42K	0.05%	541
2020 Q4	$720K	Sell	32,676 -72,314	-69%	-$1.59M	0.05%	593
2020 Q3	$1.89M	Buy	104,990 +39,496	+60%	+$818K	0.06%	553
2020 Q2	$1.66M	Sell	65,494 -20,795	-24%	-$448K	0.04%	740
2020 Q1	$1.58M	Sell	86,289 -74,163	-46%	-$1.44M	0.04%	640
2019 Q4	$3.54M	Buy	160,452 +125,297	+356%	+$2.52M	0.05%	595
2019 Q3	$505K	Buy	+35,155	New	+$502K	0.01%	1087

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Winton Group's DRNA Position: Q4 2021 in Review

Winton Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 30,485 shares — an estimated $615K sold.

Winton Group first reported a position in DRNA in Q3 2019 and held it in 9 quarters. The position peaked at $3.54M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Winton Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Winton Group sold 30,485 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $615K.
Winton Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and held it in 9 quarters.
Winton Group's Dicerna Pharmaceuticals, Inc. position peaked at $3.54M in Q4 2019.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.